Multicentric Castleman disease in a patient infected with the human immunodeficiency virus
DOI:
https://doi.org/10.5935/2764-734X.e202205010Keywords:
Castleman Diseas, Lymphoma, AIDS-Related, Herpesvirus 8, Human, Systemic Inflammatory Response Syndrome, Sarcoma, KaposiAbstract
Castleman disease is a rare lymphoproliferative disorder with distinct clinical, histological and etiological presentations that may present as localized lymphadenopathy or systemic disease. The presentation of multicentric Castleman Disease is associated with human herpes virus-8, especially in patients infected with the human immunodeficiency virus and occasionally found with Kaposi’s Sarcoma. We present a case rarely described in the literature of a 41-year-old man with a recent diagnosis of human immunodeficiency virus infection and high viral load who developed peripheral lymph node enlargement associated with multicentric Castleman Disease and Kaposi’s Sarcoma after starting antiretroviral therapy.
Downloads
References
1. Cabot RC, Founder BC, Town VW. Case records of the Massachusetts general hospital weekly clinicopathological exercises: case 40011. N Engl J Med. 1954 Jan;250(1):26-30. DOI: https://www.nejm.org/doi/full/10.1056/NEJM195401072500107
2. Haq IU, Pria AD, Papanastasopoulos P, Stegmann K, Bradshaw D, Nelson M, et al. The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients. HIV Med. 2016 Jan;17(1):56-61.
3. Mylona EE, Baraboutis IG, Lekakis LJ, Ourania G, Papastamopoulos VV, Skoutelis A. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008 Jan/Mar;10(1):25-35.
4. Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018 Jan;180(2):206-16.
5. Uldrick TS, Wang V, O’Mahony D, Aleman K, Wyvill KM, Marshall V, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010 Ago;51(3):350-8.
6. Lachant NA, Sun NC, Leong LA, Oseas RS, Prince HE. Multicentric angiofollicular lymph node hyperplasia (Castleman’s disease) followed by Kaposi’s sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985 Jan;83(1):27-33.
7. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood. 2001 Abr;97(8):2526-7.
8. Bower M, Newsom-Davis T, Naresh K, Merchant S, Lee B, Gazzard B, et al. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011 Jun;29(18):2481-6.
9. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard J. Human herpesvirus 8-positive Castleman disease in human immunodeficiency vírus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis. 2002 Out;35(7):880-2.
10. Zietz C, Bognor JR, Goebel FD, Löhrs U. An unusual cluster of cases of Castleman’s disease during highly active antiretroviral therapy for AIDS. N Engl J Med. 1999 Jun;340(24):1923-4.
11. Lee SM, Edwards SG, Chilton DN, Ramsay A, Miller RF. Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multicentric Castleman’s disease. Haematologica. 2010;95(11):1979-81.
12. Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009 Abr;20(4):775-9.
13. Oksenhendler E, Boulanger E, Galicier L, Ming-Qing D, Dupin N, Diss TC, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002 Abr;99(7):2331-6.
14. Bottieau E, Colebunders R, Schroyens W, Van Droogenbroeck J, Droogh E, Depraetere K, et al. Multicentric Castleman’s disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin. 2000;55:97-101.
15. Goncalves PH, Ziegelbauer J, Uldrick TS, Yarchoan R. Kaposi sarcoma herpesvirus-associated cancers and related diseases. Curr Opin HIV AIDS. 2017 Jan;12(1):47-56.
16. Guo WX, Antakly T, Cadotte M, Kachra Z, Kunkel L, Masood R, et al. Expression and cytokine regulation of glucocorticoid receptors in Kaposi’s sarcoma. Am J Pathol. 1996 Jun;148(6):1999-2008.
17. Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Marshall V, Wang V, et al. Clinical features and outcomes of patients with symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated inflammation: Prospective characterization of KSHV inflammatory cytokine syndrome (KICS). Clin Infect Dis. 2016 Mar;62(6):730-8.
18. Uldrick TS, Polizzotto MN, Aleman K, Wyvill KM, Marshall V, Whitby D, et al. Rituximab plus liposomal doxorubicin in HIV infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014 Dez;124(24):3544-52.
19. Hofmann C, Schmid H, Müller M, Teutsch C, Van Lunzen J, Esser S, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011 Set;118(13):3499-503
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Infections in Evidence
This work is licensed under a Creative Commons Attribution 4.0 International License.
All users may freely read, download, share, and adapt this scientific product for any purpose (even commercial ones), provided that due credit is given to the authors and the original publication, and that any alterations are duly indicated.
> Ethics
All articles published herein have received ethical approval from the National Research Ethics System (formerly CEP/CONEP system) based on Federal Law 14.874/24 and other specific Brazilian regulations, or a similar document attesting to the knowledge and authorization from the institution of origin in the case of foreign works.
The authors declare that there is no sponsorship or conflict of interest of any kind, unless otherwise indicated in the body of the article.
It is worth noting that case reports are a valuable learning resource for the scientific community, but should not be used in isolation to guide diagnostic or therapeutic options in clinical practice or health policies
